A citation-based method for searching scientific literature

Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff, Christian Brandts, Enric Carcereny, Jesús Corral, Anne-Marie C Dingemans, Eva Pereira, Jana Fassunke, Rieke N Fischer, Masyar Gardizi, Lukas Heukamp, Amelia Insa, Anna Kron, Roopika Menon, Thorsten Persigehl, Martin Reck, Richard Riedel, Sacha I Rothschild, Andreas H Scheel, Matthias Scheffler, Petra Schmalz, Egbert F Smit, Meike Limburg, Mariano Provencio, Niki Karachaliou, Sabine Merkelbach-Bruse, Martin Hellmich, Lucia Nogova, Reinhard Büttner, Rafael Rosell, Jürgen Wolf. J Thorac Oncol 2019
Times Cited: 44







List of co-cited articles
440 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].
Zhong-Zhen Guan, Li Zhang, Long-Yun Li, Guo-Liang Jiang, Xu-Yi Liu, Da-Tong Chu, Hong-Yun Zhao, Wei Li. Ai Zheng 2005
12
8

Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Inger Johanne Zwicky Eide, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicenas, Jussi Koivunen, Bjørn Henning Grønberg, Odd Terje Brustugun. Lung Cancer 2020
18
5

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Edward B Garon, Jill M Siegfried, Laura P Stabile, Patricia A Young, Diana C Marquez-Garban, David J Park, Ravi Patel, Eddie H Hu, Saeed Sadeghi, Rupesh J Parikh,[...]. Lung Cancer 2018
24
4

Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank.
Andrea V Margulis, Manel Pladevall, Nuria Riera-Guardia, Cristina Varas-Lorenzo, Lorna Hazell, Nancy D Berkman, Meera Viswanathan, Susana Perez-Gutthann. Clin Epidemiol 2014
232
2

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Baohui Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Yizhuo Zhao,[...]. JAMA Oncol 2018
218
2

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
Ying Cheng, Qiming Wang, Kai Li, Jianhua Shi, Ying Liu, Lin Wu, Baohui Han, Gongyan Chen, Jianxing He, Jie Wang,[...]. Br J Cancer 2021
20
5

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Natasha B Leighl, Naiyer A Rizvi, Lopes Gilberto de Lima, Wichit Arpornwirat, Charles M Rudin, Alberto A Chiappori, Myung-Ju Ahn, Laura Q M Chow, Lyudmila Bazhenova, Arunee Dechaphunkul,[...]. Clin Lung Cancer 2017
24
4

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia,[...]. J Thorac Oncol 2020
30
3

Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Songwen Zhou, Shengxiang Ren, Lianghua Yan, Ling Zhang, Liang Tang, Jie Zhang, Caicun Zhou. Respirology 2009
24
4



Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
David R Spigel, Howard A Burris, F Anthony Greco, Kent C Shih, Victor G Gian, Andrew J Lipman, Davey B Daniel, David M Waterhouse, Lindsey Finney, John V Heymach,[...]. Cancer 2018
8
12

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Suresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, Carlos H Barrios, Keunchil Park, Isabel Bover, Dae Seog Heo, Rafael Rosell, Denis C Talbot, Richard Frank,[...]. J Clin Oncol 2012
204
2

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Shirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J Hochmair, Philip Clingan, Steven F Powell,[...]. J Clin Oncol 2020
294
2

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.
Xingsheng Hu, Li Zhang, Yuankai Shi, Caicun Zhou, Xiaoqing Liu, Dong Wang, Yong Song, Qiang Li, Jifeng Feng, Shukui Qin,[...]. PLoS One 2015
10
10

Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
Keke Nie, Zhongfa Zhang, Chunling Zhang, Chuanxin Geng, Ling Zhang, Xiajuan Xu, Shichao Liu, Songping Wang, Xingjun Zhuang, Ketao Lan,[...]. Lung Cancer 2018
24
4

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
Yuichiro Ohe, Fumio Imamura, Naoyuki Nogami, Isamu Okamoto, Takayasu Kurata, Terufumi Kato, Shunichi Sugawara, Suresh S Ramalingam, Hirohiko Uchida, Rachel Hodge,[...]. Jpn J Clin Oncol 2019
54
2

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
David R Spigel, Howard A Burris, F Anthony Greco, Dianna L Shipley, Elke K Friedman, David M Waterhouse, Robert C Whorf, R Brian Mitchell, Davey B Daniel, Jeffrey Zangmeister,[...]. J Clin Oncol 2011
131
2

Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Filippo de Marinis, Konstantin K Laktionov, Artem Poltoratskiy, Inna Egorova, Maximilian Hochmair, Antonio Passaro, Maria Rita Migliorino, Giulio Metro, Maya Gottfried, Daphne Tsoi,[...]. Lung Cancer 2021
3
33


Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
James Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, Suresh S Ramalingam, Lecia V Sequist, Wu-Chou Su, Sang-We Kim, Joo-Hang Kim, David Planchard, Enriqueta Felip,[...]. J Clin Oncol 2017
357
2

Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001).
Masayoshi Miyawaki, Katsuhiko Naoki, Satoshi Yoda, Sohei Nakayama, Ryosuke Satomi, Takashi Sato, Shinnosuke Ikemura, Keiko Ohgino, Kota Ishioka, Daisuke Arai,[...]. Mol Clin Oncol 2017
8
12

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Jonathan W Goldman, Julien Mazieres, Fabrice Barlesi, Konstantin H Dragnev, Marianna Koczywas, Tuncay Göskel, Alexis B Cortot, Nicolas Girard, Claas Wesseler, Helge Bischoff,[...]. Front Oncol 2020
19
5

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
Ken Uchibori, Miyako Satouchi, Naoko Sueoka-Aragane, Yoshiko Urata, Akemi Sato, Fumio Imamura, Takako Inoue, Motoko Tachihara, Kazuyuki Kobayashi, Nobuyuki Katakami,[...]. Lung Cancer 2018
11
9

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Baohui Han, Kai Li, Yizhuo Zhao, Baolan Li, Ying Cheng, Jianying Zhou, You Lu, Yuankai Shi, Zhehai Wang, Liyan Jiang,[...]. Br J Cancer 2018
125
2

Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer.
Huiyan Deng, Bin Li, Lina Li, Jingcui Peng, Tongshuai Lv, Yueping Liu, Cuimin Ding. Pathol Res Pract 2019
3
33

Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Jing Deng, Wei Jia Fang, Xiao Chen Zhang, Dong Ping Wu, Hong Ming Fang, Jing Chen, Jiong Qian, Hai Bo Mou, Bin Bin Chu, Nong Xu,[...]. Med Oncol 2012
3
33

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Athanasios G Pallis, Alexandra Voutsina, Nikolaos Kentepozidis, Stylianos Giassas, Pavlos Papakotoulas, Sofia Agelaki, Kostas Tryfonidis, Athanasios Kotsakis, Lambros Vamvakas, Nikolaos Vardakis,[...]. Clin Lung Cancer 2012
7
14

Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial.
Óscar Juan, Francisco Aparisi, Alfredo Sánchez-Hernández, José Muñoz-Langa, Gaspar Esquerdo, José García-Sánchez, Antonio López, Javier Garde, Vicente Giner. Clin Lung Cancer 2015
12
8

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Tudor Ciuleanu, Lilia Stelmakh, Saulius Cicenas, Skaidrius Miliauskas, Alexandru Calin Grigorescu, Carina Hillenbach, Hrefna Kristin Johannsdottir, Barbara Klughammer, Emilio Esteban Gonzalez. Lancet Oncol 2012
307
2

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
969
2

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Joel W Neal, Suzanne E Dahlberg, Heather A Wakelee, Seena C Aisner, Michaela Bowden, Ying Huang, David P Carbone, Gregory J Gerstner, Rachel E Lerner, Jerome L Rubin,[...]. Lancet Oncol 2016
79
2

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer, Brad Kahl, Nora Cavazos, Black Liu, Shiyi Yang, Fong Clow,[...]. Br J Haematol 2017
75
2

[Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
Zhe-Sheng Wen, Xiao-Qin Chen, Hai-Ying Wu, Wei-Dong Wei, Tie-Hua Rong. Ai Zheng 2007
1
100

The ever-increasing importance of cancer as a leading cause of premature death worldwide.
Freddie Bray, Mathieu Laversanne, Elisabete Weiderpass, Isabelle Soerjomataram. Cancer 2021
97
2

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Hiroaki Akamatsu, Nobuyuki Katakami, Isamu Okamoto, Terufumi Kato, Young Hak Kim, Fumio Imamura, Masaharu Shinkai, Rachel A Hodge, Hirohiko Uchida, Toyoaki Hida. Cancer Sci 2018
37
2

Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Kazuhiko Yamada, Koichi Takayama, Satoru Kawakami, Kouichi Saruwatari, Ryotaro Morinaga, Taishi Harada, Naoko Aragane, Shuya Nagata, Junji Kishimoto, Yoichi Nakanishi,[...]. Jpn J Clin Oncol 2013
11
9

A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Toshihide Yokoyama, Hiroshige Yoshioka, Daichi Fujimoto, Yoshiki Demura, Katsuya Hirano, Takahiro Kawai, Ryogo Kagami, Yasuyoshi Washio, Tadashi Ishida, Mariko Kogo,[...]. Lung Cancer 2019
12
8

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Oscar Arrieta, Feliciano Barrón, Miguel-Ángel Salinas Padilla, Alejandro Avilés-Salas, Laura Alejandra Ramírez-Tirado, Manuel Jesús Arguelles Jiménez, Edgar Vergara, Zyanya Lucia Zatarain-Barrón, Norma Hernández-Pedro, Andrés F Cardona,[...]. JAMA Oncol 2019
70
2


Gefitinib plus Fuzheng Kang'ai Formula () in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial.
Xiao-Bing Yang, Xiao-Shu Chai, Wan-Yin Wu, Shun-Qin Long, Hong Deng, Zong-Qi Pan, Wen-Feng He, Yu-Shu Zhou, Gui-Ya Liao, Shu-Jing Xiao. Chin J Integr Med 2018
12
8

A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
Yasuyuki Ikezawa, Hajime Asahina, Satoshi Oizumi, Masahiro Watanabe, Kei Takamura, Yasutaka Kawai, Noriyuki Yamada, Toshiyuki Harada, Ichiro Kinoshita, Yuka Fujita,[...]. Cancer Chemother Pharmacol 2017
10
10

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
Jianya Zhou, Jing Zheng, Xiaochen Zhang, Jing Zhao, Yanping Zhu, Qian Shen, Yuehong Wang, Ke Sun, Zeying Zhang, Zhijie Pan,[...]. BMC Cancer 2018
17
5

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Seung Tae Kim, Ji Eun Uhm, Jeeyun Lee, Jong-mu Sun, Insuk Sohn, Seon Woo Kim, Sin-Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park,[...]. Lung Cancer 2012
79
2

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
James Chih-Hsin Yang, Frances A Shepherd, Dong-Wan Kim, Gyeong-Won Lee, Jong Seok Lee, Gee-Chen Chang, Sung Sook Lee, Yu-Feng Wei, Yun Gyoo Lee, Gianluca Laus,[...]. J Thorac Oncol 2019
93
2

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Yi-Long Wu, Jin Soo Lee, Sumitra Thongprasert, Chong-Jen Yu, Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu,[...]. Lancet Oncol 2013
235
2

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee. Cancer Res Treat 2020
2
50

Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Baohui Han, Bo Jin, Tianqing Chu, Yanjie Niu, Yu Dong, Jianlin Xu, Aiqing Gu, Hua Zhong, Huimin Wang, Xueyan Zhang,[...]. Int J Cancer 2017
56
2

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
2

Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Naruo Yoshimura, Shinzoh Kudoh, Shigeki Mitsuoka, Naoki Yoshimoto, Takako Oka, Toshiyuki Nakai, Tomohiro Suzumira, Kuniomi Matusura, Yoshihiro Tochino, Kazuhisa Asai,[...]. Lung Cancer 2015
34
2


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.